The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques.

  title={The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques.},
  author={Ronan Y. Depoort{\`e}re and Tom H. Johnston and Susan H. Fox and Jonathan M. Brotchie and Adrian Newman-Tancredi},
  journal={Parkinsonism \& related disorders},

The selective 5-HT1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat

It is suggested that selective and highly efficacious 5-HT1A agonists, such as NLX-112, may be useful in combating tetrabenazine-induced Parkinsonism and/or depression in Huntington’s disease patients.

The selective 5-HT1A receptor agonist NLX-112 displays anxiolytic-like activity in mice

NLX-112 may possess anxiolytic properties which complement its known activity in models of movement disorders, and befiradol, a highly selective, potent and efficacious 5-HT1A receptor full agonist, may be associated with anxiety-like behaviours in mice.

The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats

Compounds selective for 5-HT1A/SERT target sites including Vilazodone and Vortioxetine significantly reduced L-DOPA-induced dyskinesia without compromising L-dOPA pro-motor efficacy, and YL-0919 failed to reduce L- DOPA- induced dyskinese management in Parkinson’s patients.

Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease

This work reviews the existing and emerging interventions for PD with focus on newly approved and investigational drugs for motor symptoms, motor fluctuations, dyskinesia, and balance and gait dysfunction.

Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials.



Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned primate model of Parkinson's disease

  • W. KoE. Pioli M. Facheris
  • Biology, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2014
It is suggested that a low‐dose combination of fenobam and amantadine can be used for alleviating dyskinesia without causing adverse motor effects and may offer a new therapeutic strategy for treatment of LID in PD patients.

Serotonergic targets for the treatment of l-DOPA-induced dyskinesia

The rationale for continued investigation of several potential anti-dyskinetic strategies including 5-HT stimulation of 5- HT1A and5-HT1B receptors and blockade of 5 -HT2A receptors and SERT is discussed.

Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia

Amantadine immediate and extended-release are effective and safe for the treatment of LIDs and may have possible effects on other PD symptoms such as apathy or fatigue.

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia

It is demonstrated that the EC50 of amantadine for reducing dyskinesia is consistent across multiple species and supports a plasma concentration target of ∼1400 ng/ml to achieve therapeutic efficacy.